Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T12:46:37.513Z.
Calculation as of: 2026-10-06T12:46:37.513Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f130e36c5816a2cced4d00ccb7d778b7baaa6bfdcaf5b95b3974dc9f748ee68d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
FibroBiologics, Inc. Common Stock
Market Cap
$2.47M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.37M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.59M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.09M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.37M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| FibroBiologics, Inc. Common Stock (FBLG) | $2.47M | N/A | N/A | N/A | N/A |
| Creative Medical Technology Holdings, Inc. (CELZ)vs › | $2.37M | N/A | N/A | N/A | N/A |
| GeoVax Labs, Inc. (GOVX)vs › | $2.36M | N/A | 0.00% | 0.00% | 0.00% |
| bioAffinity Technologies, Inc. (BIAF)vs › | $2.59M | N/A | N/A | N/A | N/A |
| Autonomix Medical, Inc. (AMIX)vs › | $1.92M | N/A | N/A | N/A | N/A |
| BioRestorative Therapies, Inc. (BRTX)vs › | $3.09M | N/A | N/A | N/A | N/A |
| Adagio Medical Holdings, Inc. (ADGM)vs › | $3.13M | N/A | N/A | N/A | N/A |
| Cadrenal Therapeutics, Inc. Common Stock (CVKD)vs › | $3.37M | N/A | N/A | N/A | N/A |
| Curis, Inc. (CRIS)vs › | $1.54M | N/A | 0.69% | 0.69% | 0.69% |
| Aethlon Medical, Inc. (AEMD)vs › | $3.44M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
